CollPlant reports positive non-clinical filler study data

CollPlant Biotechnologies Ltd. furnished a Form 6-K to provide investors with a press release dated September 30, 2025.

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. furnished a Form 6-K to provide investors with a press release dated September 30, 2025. In this release, the company reports positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, a product candidate in its regenerative medicine portfolio. The first and fourth paragraphs of the press release are also incorporated by reference into several of CollPlant’s effective shelf and employee incentive registration statements, so that the new information forms part of those securities offering documents.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CollPlant Biotechnologies (CLGN) report in this Form 6-K?

CollPlant Biotechnologies reported that it issued a press release titled “CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler” dated September 30, 2025.

What product is mentioned in the CollPlant (CLGN) September 2025 Form 6-K?

The filing refers to a photocurable regenerative dermal and soft tissue filler, for which CollPlant reported positive results from non-clinical studies.

How is the press release used in CollPlant’s existing SEC registration statements?

The filing states that the first and fourth paragraphs of the press release are incorporated by reference into CollPlant’s Form S-8 and Form F-3 registration statements, making that information part of those offering documents from the report date.

Does this CollPlant (CLGN) Form 6-K include financial results?

No financial results are presented. The Form 6-K focuses on the scientific and product development update related to non-clinical study results for the dermal and soft tissue filler.

Why is CollPlant’s positive non-clinical study news in an SEC filing?

CollPlant used Form 6-K to furnish the press release to U.S. investors and to formally incorporate key parts of it into existing SEC registration statements used for securities offerings and employee equity plans.

Who signed the CollPlant (CLGN) September 30, 2025 Form 6-K?

The Form 6-K was signed on behalf of CollPlant Biotechnologies Ltd. by Eran Rotem, who is identified as Deputy CEO and Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/30/2025 - 07:22 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

The first and fourth paragraphs of the press release attached to this Form 6-K are hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479, 333-263842, 333-271320 and 333-279791) and Form F-3 (File No. 333-238731 and 333-269087), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Form 20-F ☒              Form 40-F ☐

On September 30, 2025, CollPlant Biotechnologies Ltd. issued a press release entitled “CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler”.

Attached hereto and incorporated by reference herein are the following exhibits:

99.1 Press Release, dated September 30, 2025

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.
Date: September 30, 2025	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

2